Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

EZH2 as novel therapeutic target for chronic kidney disease

Nov. 12, 2020

Janssen Pharmaceutica discloses BARK1 inhibitors

Nov. 11, 2020

Phase III CARDINAL study of bardoxolone in Alport syndrome meets primary endpoint

Nov. 10, 2020

Phase III trial of Nefecon in primary IgAN meets key endpoints

Nov. 9, 2020

CaMK4 as potential target to slow cyst growth in PKD

Nov. 9, 2020

SYNB-8802 consumes GI oxalate in animals with acute hyperoxaluria

Nov. 6, 2020

Synlogic advances SYNB-8802 into phase I study for treatment of enteric hyperoxaluria

Nov. 5, 2020

Phase III results for molidustat in patients with renal anemia undergoing dialysis

Nov. 4, 2020

dEF-3122 improves inflammation and fibrosis in liver and kidneys of NASH mice

Nov. 3, 2020

First-in-class LDHA inhibitor CHK-336 for treating primary hyperoxaluria

Nov. 3, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...